CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 52 enrolled
Drug / intervention
ZULRESSO®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05059600
NCT05059600Phase 4Completed
CompareCT.gov

Assessment of Safe-use Conditions for Administration of ZULRESSO in a Home Setting

Supernus Pharmaceuticals, Inc.·interventional·Posted Sep 28, 2021·Updated Sep 15, 2025

In Brief

A Phase 4 clinical trial evaluating ZULRESSO® for Postpartum Depression. Completed, enrolled 52 participants across 6 sites.

Detailed Summary

The primary purpose of this study was to evaluate whether the safe-use conditions for administration of brexanolone (ZULRESSO®) can be implemented in a home setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostpartum Depression
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedSep 28, 2021
Enrollment StartOct 8, 2021
Primary CompletionJul 14, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.8 years ago

Interventions

ZULRESSO®drug

Intravenous infusion of ZULRESSO®.